纈苯那嗪二甲苯磺酸鹽 Valbenazine Tosylate

一、產品概述

      Valbenazine Tosylate由Neurocrine Biosciences研發，用于治療亨廷頓舞蹈癥和遲發性運動障礙。于2017年4月11日獲得美國食品藥品監督管理局（FDA）批準上市，化合物專利2029年到期。

二、主要產品

Description	Structural Formula	CAS No.	Category
Valbenazine Tosylate		1639208-54-0	API
2-acetyl-N,N,N,4-tetramethylpentan-1- aminium iodide		1069-62-1	Intermediate
6,7-dimethoxy-3,4-dihydroisoquinoline hydrochloride		20232-39-7	Intermediate
(S)-2-((tert-butoxycarbonyl)amino)-3-methylbutanoic acid		13734-41-3	Intermediate

Note: Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes patent infringement and its liability is at buyer's risk.